While this is not (in any way) going to affect Merck’s near-term NYSE stock price, it is fascinating — courtesy of one of my anonymous commenters:
. . . . Anonymous said…
FYI, the compound licensed from Yamasa (i.e. EFda — 4’-ethynyl-2-fluoro-2’-deoxyadenosine) is in fact a flavour agent (note that Yamasa is a soy sauce company). Its ability to act as an inhibitor of HIV reverse transcriptase is a pleasant surprise.
July 25, 2012 7:02 PM. . . .
Who knew? S/he did, of course — nice find!
Having said that, it must be absolutely clear from the Japanese and US patent filings that Yamasa owns the worldwide exclusive rights to the 4’-ethynyl-2-fluoro-2’-deoxyadenosine protien structure — otherwise, why would Merck bother to pay for a food flavor agent? In short, it wouldn’t. Here’s to hoping for an advance — toward a cure!